论文部分内容阅读
目的探讨血浆氨基末端脑钠肽前体(NT-proBNP)水平对重度及以上慢性阻塞性肺疾病(COPD)患者肺功能的预测价值。方法 67例COPD患者根据肺功能分成中度组(35例)与重度及以上组(32例)。用电化学发光免疫分析技术(ECLIA)检测血浆中的NT-proBNP水平。两组数据间的比较采用成组t检验,相关性分析采用Spearman秩相关分析。用ROC曲线进行诊断价值的判定。结果两组患者血浆NT-proBNP水平、FEV1及FEV1%比较差异均有统计学意义(均P<0.05),NT-proBNP与FEV1%间存在负相关。NT-proBNP的诊断界点为1 105 pg/ml,敏感度0.906,特异度0.943,曲线下面积0.934。结论血浆NT-proBNP水平可作为预测COPD患者肺功能程度的一个有价值的指标。
Objective To investigate the predictive value of plasma NT-proBNP levels in patients with severe chronic obstructive pulmonary disease (COPD) and pulmonary function. Methods 67 COPD patients were divided into moderate group (35 cases) and severe group (32 cases) according to pulmonary function. Plasma levels of NT-proBNP were measured by electrochemiluminescence immunoassay (ECLIA). Comparisons between the two groups of data using group t-test, correlation analysis using Spearman rank correlation analysis. ROC curve with the diagnostic value of the decision. Results There were significant differences in plasma NT-proBNP levels, FEV1 and FEV1% between the two groups (all P <0.05), and there was a negative correlation between NT-proBNP and FEV1%. The cut-off point for NT-proBNP was 1 105 pg / ml, with a sensitivity of 0.906 and a specificity of 0.943, with an area under the curve of 0.934. Conclusion Plasma NT-proBNP level can be used as a valuable index to predict the degree of pulmonary function in COPD patients.